CNCE - Concert Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
9.44
-0.40 (-4.07%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close9.84
Open9.84
Bid8.00 x 900
Ask11.50 x 1300
Day's Range9.30 - 9.97
52 Week Range9.30 - 21.00
Volume347,813
Avg. Volume288,090
Market Cap222.117M
Beta (3Y Monthly)0.64
PE Ratio (TTM)N/A
EPS (TTM)-2.40
Earnings DateNov 6, 2017 - Nov 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.00
Trade prices are not sourced from all markets
  • Concert Pharma Initiates Early-Stage Schizophrenia Study
    Zacks9 days ago

    Concert Pharma Initiates Early-Stage Schizophrenia Study

    Concert Pharmaceuticals (CNCE) announces initiation of multiple-ascending dose phase I study to evaluate its pipeline candidate, CTP-692, as an adjunctive treatment for schizophrenia.

  • Business Wire9 days ago

    Concert Pharmaceuticals to Present CTP-543 Phase 2 Interim Data in Alopecia Areata at 2019 World Congress for Hair Research Annual Meeting

    Concert Pharmaceuticals, Inc. (CNCE) today announced that interim clinical data from its CTP-543 Phase 2 trial in alopecia areata will be presented in a poster presentation and a sponsored lecture at the 11th Annual World Congress for Hair Research (WCHR) being held April 24-27, 2019 in Sitges, Barcelona.

  • Business Wire10 days ago

    Concert Pharmaceuticals Initiates Phase 1 Multiple-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia

    Concert Pharmaceuticals, Inc. (CNCE) today announced that it has initiated an additional trial in the Phase 1 program evaluating CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive treatment for schizophrenia. The Phase 1 multiple-ascending dose trial will evaluate the safety, tolerability, and pharmacokinetic profile of CTP-692 in healthy volunteers. “The Phase 1 studies evaluating the dosing and safety of CTP-692 are expected to support advancement into an efficacy study in patients with schizophrenia later this year.

  • MarketWatch11 days ago

    Concert Pharmaceuticals' stock takes a sharp dive after disappointing patent appeal board ruling

    Shares of Concert Pharmaceuticals Inc. took a sharp afternoon dive Monday, after the biopharmaceutical company said the patent trial and appeal board found that the claims of the patent on its alopecia areata treatment CTP-543 were "not patentable." The stock, which was little changed in afternoon trade just prior to the announcement, plunged 17% toward a 2-year low after the announcement. The company said the decision was appealable to the U.S. court of appeals. "While we're disappointed in this outcome, we believe we have strong arguments supporting the validity of our patent and intend to appeal the decision as we work to create additional intellectual property protecting CTP-543," said Chief Executive Roger Tung. In April 2017, Incyte Corp. had filed a petition challenging the validity of the patent on CTP-543. Incyte's stock slipped 0.1%. Over the past 12 months, Concert's stock has tumbled 43%, Incyte shares have rallied 29%, the iShares Nasdaq Biotechnology ETF has climbed 13% and the S&P 500 has gained 11%.

  • Business Wire11 days ago

    Concert Pharmaceuticals Announces Decision from Patent Trial and Appeal Board in IPR Proceeding

    Concert Pharmaceuticals, Inc. (CNCE) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued a final written decision in connection with the inter partes review (IPR) of U.S. Patent No. 9,249,149 (the ‘149 patent). While PTAB found that the claims of the '149 patent are not patentable, the IPR decision is appealable to the U.S. Court of Appeals for the Federal Circuit, and Concert remains committed to defending the ‘149 patent.

  • New Strong Sell Stocks for March 25th
    Zacks26 days ago

    New Strong Sell Stocks for March 25th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.

  • New Strong Sell Stocks for March 12th
    Zackslast month

    New Strong Sell Stocks for March 12th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today:

  • Business Wirelast month

    Concert Pharmaceuticals to Present at Upcoming Oppenheimer Healthcare Conference

    Concert Pharmaceuticals, Inc. today announced that it will present a corporate overview at the Oppenheimer 29th Annual Healthcare Conference on March 19, 2019 at 1:00 p.m.

  • Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed
    Zackslast month

    Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed

    Vertex's (VRTX) two phase III studies evaluating a triple combination regimen of VX-445 plus tezacaftor and ivacaftor meet the primary endpoint. The company delays filing for U.S. approval.

  • Business Wirelast month

    Concert Pharmaceuticals Announces Initiation of Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata

    Concert Pharmaceuticals, Inc. (CNCE) today announced that it has initiated an open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata. The trial is intended to inform the optimal dosing regimen for CTP-543 for future clinical trials. This open label trial follows the announcement of positive results from an interim analysis of an ongoing placebo-controlled Phase 2 trial that showed significant hair regrowth at 24 weeks with 8 mg twice-daily dosing of CTP-543.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of CNCE earnings conference call or presentation 28-Feb-19 1:30pm GMT

    Full Year 2018 Concert Pharmaceuticals Inc Earnings Call

  • Business Wire2 months ago

    Concert Pharmaceuticals Presents Interim CTP-543 Phase 2 Data in Alopecia Areata during Late-Breaker Session at American Academy of Dermatology Annual Meeting

    Concert Pharmaceuticals, Inc. (CNCE) today announced that interim results from its Phase 2 clinical trial evaluating its product candidate CTP-543 in patients with moderate-to-severe alopecia areata will be presented in an oral presentation during the late-breaking clinical trials session at the American Academy of Dermatology (AAD) Annual Meeting on March 2, 2019, in Washington, DC. The interim results from this dose-ranging trial showed that treatment with CTP-543 administered at an 8 mg twice-daily dose for 24 weeks met the primary endpoint with a statistically significant greater hair regrowth responder rate compared to placebo.

  • Concert Pharmaceuticals, Inc. (CNCE) Q4 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    Concert Pharmaceuticals, Inc. (CNCE) Q4 2018 Earnings Conference Call Transcript

    CNCE earnings call for the period ending December 31, 2018.

  • Business Wire2 months ago

    Concert Pharmaceuticals Reports Year Ended 2018 Financial Results and Provides Update on Clinical Programs

    Significant Clinical Progress in 2018; Multiple Trials with Milestones in 2019

  • Business Wire2 months ago

    Concert Pharmaceuticals to Report Full Year 2018 Results on February 28, 2019

    Concert Pharmaceuticals, Inc. today announced that it will report its financial results for the year ended December 31, 2018, on Thursday, February 28, 2019, before the U.S.

  • Concert Pharmaceuticals, Inc. (NASDAQ:CNCE): Time For A Financial Health Check
    Simply Wall St.2 months ago

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE): Time For A Financial Health Check

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Zero-debt allows substantial financial flexibility, especially forRead More...

  • GlobeNewswire2 months ago

    Analysis: Positioning to Benefit within Masco, Ascena Retail Group, Leidos, NetScout, MYR Group, and Concert Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire2 months ago

    Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at 2019 AAD Annual Meeting

    Concert Pharmaceuticals, Inc. (CNCE) today announced that interim clinical data from its CTP-543 Phase 2 trial in alopecia areata has been selected for an oral presentation at the Late-Breaking Research Program during the American Academy of Dermatology (AAD) Annual Meeting being held March 1 - 5, 2019 in Washington, D.C. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib, a drug which inhibits Janus kinases 1 and 2 (JAK1 and JAK2) and is commercially available under the name Jakafi® in the United States for the treatment of certain blood disorders. Deuterium modification of ruxolitinib was found to alter its human pharmacokinetics in ways which may enhance its use as a treatment for alopecia areata.

  • Mizuho's 9 Best Biotech Stocks to Buy for 2019
    Kiplinger2 months ago

    Mizuho's 9 Best Biotech Stocks to Buy for 2019

    Biotech stocks are a staple among growth investors. The rewards can be staggering - prices on biotechnology shares can literally double overnight - but the risk is just as high. It's not unusual for these stocks to be cut in half or worse if drug-trial data disappoints or a drug application is rejected. Thus, proper due diligence is critical, and that includes tapping the experts for information about these often difficult-to-gauge stocks. Mizuho Securities has recently put out an analyst report highlighting its top biotechnology picks for 2019. And thanks to analyst ranking service TipRanks, we can see that the report's author, Managing Director Difei Yang, has a strong track record of stock recommendations. Yang is ranked in the top 250 out of more than 5,100 tracked analysts. Yang writes, "We favor innovative and ground-breaking therapies in 2019; emerging technologies such as gene therapy and cell therapy could command substantial premiums from large cap pharma/biotech if impressive results are shown in historically difficult-to-treat conditions." As Yang points out, pharma M&A; is off to a strong start in 2019 with a number of blockbuster deals. They include Bristol-Myers Squibb's (BMY) $74 billion acquisition of Celgene (CELG), and Eli Lilly's (LLY) $8 billion buyout of Loxo Oncology (LOXO). "In our view, the transactions underscore the persistent need by large pharma to fuel continued growth and replenish R&D; pipelines via M&A;," she writes. Here are Mizuho's top nine biotech stocks to buy right now. Many of them can stand on their own but look even better as potential buyout targets. ### SEE ALSO: 19 Best Stocks to Buy for 2019 (And 5 to Sell)

  • Business Wire3 months ago

    Concert Pharmaceuticals Initiates Phase 1 Single-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia

    Concert Pharmaceuticals, Inc. (CNCE) today announced that it has initiated the second Phase 1 clinical trial with CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive treatment for schizophrenia. The Phase 1 single-ascending dose trial will evaluate the safety, tolerability, and pharmacokinetic profile of CTP-692 in healthy volunteers. “For decades all approved schizophrenia drugs have acted predominantly by modulation of dopamine, or dopamine and serotonin receptors.

  • Business Wire3 months ago

    Concert Pharmaceuticals Completes Enrollment of 12 mg Cohort in Phase 2a Trial of CTP-543 in Alopecia Areata

    Concert Pharmaceuticals, Inc. (CNCE) today announced that it has completed patient enrollment of the final cohort evaluating 12 mg twice daily of CTP-543 in its Phase 2a trial for the treatment of moderate-to-severe alopecia areata. The trial previously enrolled patients to receive 4 mg and 8 mg twice daily compared to placebo. Data from the Phase 2a trial including the 12 mg cohort is expected in the third quarter of 2019.

  • How Much Are Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Insiders Spending On Buying Shares?
    Simply Wall St.4 months ago

    How Much Are Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Insiders Spending On Buying Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...

  • Do Hedge Funds Love Concert Pharmaceuticals Inc (CNCE)?
    Insider Monkey4 months ago

    Do Hedge Funds Love Concert Pharmaceuticals Inc (CNCE)?

    Concerns over rising interest rates and expected further rate increases have hit several stocks hard since the end of the third quarter. NASDAQ and Russell 2000 indices are already in correction territory. More importantly, Russell 2000 ETF (IWM) underperformed the larger S&P 500 ETF (SPY) by about 4 percentage points in the first half of […]

  • Business Wire4 months ago

    Concert Pharmaceuticals Initiates Phase 1 Clinical Program of CTP-692 for the Treatment of Schizophrenia

    Concert Pharmaceuticals, Inc. (CNCE) today announced that it has initiated its Phase 1 clinical program for CTP-692, which is being developed as a novel adjunctive treatment for schizophrenia, a devastating, chronic illness with significant unmet need. CTP-692 is a deuterated form of D-serine, an endogenous co-agonist of the N-methyl-D-aspartate (NMDA) receptor, which has been demonstrated to be important to mood, memory, and cognition. Concert’s Phase 1 program will include a crossover pharmacokinetic comparison of CTP-692 to D-serine and single- and multiple-ascending dose studies to assess the safety, tolerability and pharmacokinetic profile of CTP-692 in healthy volunteers.

  • Vertex's (VRTX) Triple Combo Cystic Fibrosis Studies Succeed
    Zacks5 months ago

    Vertex's (VRTX) Triple Combo Cystic Fibrosis Studies Succeed

    Vertex's (VRTX) two phase III studies evaluating a triple combination regimen of VX-659 plus tezacaftor and ivacaftor meet the primary endpoint. Stock rises almost 5%.